Authors: Grace Monica P. Ibaviosa, MD; Johanna O. Flordelis, MD and Johannes F. Dayrit, MD, FPDS
Bullous systemic lupus erythematosus (BSLE) is an autoimmune-mediated, chronic, widespread, non-scarring, sub-epidermal blistering skin disease. It is typically caused by autoantibodies against type VII collagen. BSLE is an uncommon manifestation of SLE and is found in less than 5% of SLE cases.
We report a case of a 21-year-old woman with a two-year history of systemic lupus erythematosus who developed multiple pruritic vesicles on the neck six weeks prior to consultation. The lesions increased in number, size, and distribution, becoming bullae on the face, trunk, upper and lower extremities. Nikolsky and Asboe – Hansen signs were negative. Mucosal involvement and visceral organ impairment were not identified on physical examination. A 4-mm skin punch biopsy of a vesicle showed a subepidermal blister. Direct immunofluorescence of perilesional skin revealed linear deposits of IgG (+1), C3 (+1), IgM (+2) and granular fibrinogen (+2) at the basement membrane zone, consistent with bullous systemic lupus erythematosus. Oral prednisone 40 mg/day and hydroxychloroquine 200mg once a day were prescribed. The lesions became dry and flat after two weeks and no new eruption was noted after three months.
Patients with BSLE manifest with a widespread symmetrical distribution of vesicular skin lesions frequently favoring the upper part of the trunk, flexural and extensor aspects of the upper extremities, neck and face but may occur anywhere on the cutaneous surface. Treatment with corticosteroids and hydroxychloroquine was effective in our case. The prognosis of BSLE is good with variable duration characterized by spontaneous exacerbations and remissions influenced more by the systemic disease rather than by the eruption hence the need to follow closely the systemic disease activity.
Ibaviosa, GM, Flordelis, J & Dayrit, J. (2017). Bubbly lupus: A case of a Filipino woman with bullous systemic lupus erythematosus successfully treated with prednisone and hydroxychloroquine. Journal of the Philippine Dermatological Society, 26(1), 65-68.
bullous systemic lupus erythematosus, lupus, prednisone, hydroxychloroquine
- Shirahama S, Yagi H, Furukawa F, Takigawa M. A Case of Bullous Systemic Lupus Erythematosus. Dermatology. 1994; 189(suppl I):95-96.
- Yung A, Oakley A. Bullous systemic lupus erythematosus. Aust J Dermatol. 2000, vol 41, no 4, pp. 234-237.
- Duan L, Chen L, Zhong S, Wang Y, Huang Y, He Y, Chen J, et al. Treatment of Bullous Systemic Lupus Erythematosus. Journal of Immunology Research, 2014 Aug. Volume 2015.
- Rothfield N, Sonthelmer RD. Lupus erythematosus; systemic and cutaneous manifestations. Clinics in Dermatology, 2006, vol 24, no 5, pp 348-362.
- Grover C, Khurana A, Sharma S, Singal A. Bullous Systemic Lupus Erythematosus. Indian J Dermatol. 2013 Nov-Dec; 58(6):492.
- Madiyal A, Ajila V, Hegde S, Babu S, Alva P. Bullous Systemic Lupus Erythematosus: Report of a rare case with oral manifestations and literature review. Balkan Military Medical Review 2015; 18(4):134-139.
- Wojnarowska F, Briggaman RA. Management of Blistering Diseases. Springer Science + Business Media, B.V. 1990; 18:264-275.
- Dos-Santos CE, Velho PHI, Marques FMM, Werner B, Aragao SC, Filho AR. Bullous systemic lupus erythematosus in a pregnant woman: a case report. Rev Bras Reumatol. 2013; 53(5):438-440.
- Tincopa M, Puttgen KB, Sule S, et al. Bullous Lupus: An Unusual Initial Presentation of Systemic Lupus Erythematosus in an Adolescent Girl. Pediatric Dermatology. 2010; 4:373-6.
- Stith RH, Erickson QL, et al. Bullous Eruption: A Manifestation of Lupus Erythematosus. Cutis. 2003; 72:31-7.
- Fujimoto W, Hamada T, Yamada J, Matsuura H, Iwatsuki K. Bullous Systemic Lupus Erythematosus as an Initial Manifestation of SLE. J Dermatol. 2005; 32:1021-27.
- Ludgate MW, Greig DE. Bullous systemic lupus erythematosus responding to dapsone. Australas J Dermatol. 2008; 49:91-3.
- Aswani V., Vaz B., et al. Bullous Systemic Lupus Erythematosus. Indian J Dermatol, Venerol and Leprol. 1993; 59(2):97-100.
- Yogarajah, M, Sivasambu, B, Jaffe EA. Case reports in Rheumatology Volume 2015. Article ID 930683.
- Vijayalakshmi AM, Jayavardhana A. Bullous Systemic Lupus Erythematosus and Lupus Nephritis in a 10-year-old Boy. Indian Pediatrics. November 2007. Vol 44; 861-863.
- Eckman JA, Mutasim DF. Bullous Sustemic Lupus Erythematosus With Milia and Calcinosis. Cutis. July 2002; 70;31-34.
- Sáez-de-Ocariz M, Espinosa-Rosales F, Lopez-Corella E, de Leon-Bojorge B. Bullous lesions as a manifestation of systemic lupus erythematosus in two Mexican teenagers Pediatric Rheumatology. 2010; 8:19.
- Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Therapeutic Advancements in Chronic Disease, July 2010; 1(4):163-175.
Authors: Katrina Carmela M. Belen, MD, DPDS, Jasmin J.Jamora, MD, FPDS , Ma. Cecilia P. Ingente MD, DPDSAbstractBackground: Dermoscopy, a non-invasive diagnostic tool, has been proven to improve the diagnostic accuracy of vascular tumors since it can aid in...
A randomized, double-blind, comparative study on the safety and efficacy of virgin coconut (Cocos nucifera l.) oil against 1% hydrocortisone lotion as an anti-inflammatory and antipruritic preparation for mosquito reactions
Authors: Uy, Veronica S, MD; Gracia B. Teodosio, MD, FPDS; Ma. Teresita G. Gabriel, MD, FPDS; Mary Catherine T. Galang, MD; Mohammad Yoga A. Waskito, MD; Johannes F. Dayrit, MD, FPDS Abstract Background: Virgin coconut oil (VCO) has been reported...
Primary Cutaneous Anaplastic Large Cell Lymphoma (PC-ALCL) is a rare Non-Hodgkin lymphoma (NHL) representing approximately 9% of all cutaneous lymphomas.3 It usually manifests as a slow-growing, solitary tumor which has a tendency to regress spontaneously. However, metastasis is reported in 5-10% of cases.